Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Melanoma × ceralasertib × Clear all

Phase

Status

Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Lung Neoplasms 3 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasms by Site 1 Neoplasms 1 Myelodysplastic Syndromes 1 Melanoma 1 Lung Diseases 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Cholangiocarcinoma 1 Carcinosarcoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Endometrioid 1 Carcinoma, Bronchogenic 1 Bronchial Neoplasms 1 Bile Duct Neoplasms 1 Advanced Solid Tumours 1 Adenocarcinoma 1

Interventions

pembrolizumab 60 Nivolumab 38 Ipilimumab 25 trametinib 11 Specimen Handling 9 Cyclophosphamide 9 dabrafenib 8 Magnetic Resonance Spectroscopy 8 fludarabine 7 CTLA-4 Antigen 7 encorafenib 6 binimetinib 6 Radiosurgery 6 Interleukin-2 6 Biopsy 6 lenvatinib 5 fludarabine phosphate 5 atezolizumab 5 Radiotherapy 5 Introns 5 Cisplatin 5 durvalumab 4 dostarlimab 4 cobimetinib 4 Pemetrexed 4 Paclitaxel 4 Interferon alpha-2 4 Carboplatin 4 tocilizumab 3 tislelizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05061134 2025-07-31

MONETTE

AstraZeneca

Phase 2 Active not recruiting

194 enrolled 21 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡